Responses
Late-breaking abstracts
Novel single-agent immunotherapies
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
Compose a Response to This Article
Other responses
No responses have been published for this article.
